Logo do repositório
 
Publicação

Rho-kinase as a therapeutic target for nonalcoholic fatty liver diseases

2021-09Recensão Acesso aberto
Ver registo simples
dc.contributor.authorSousa-Lima, Inês
dc.contributor.authorKim, Hyun Jeong
dc.contributor.authorJones, John
dc.contributor.authorKim, Young Bum
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.institutionCentro de Estudos de Doenças Crónicas (CEDOC)
dc.contributor.pblKorean Diabetes Association
dc.date.accessioned2021-11-03T05:03:12Z
dc.date.available2021-11-03T05:03:12Z
dc.date.issued2021-09
dc.description.abstractNonalcoholic fatty liver disease (NAFLD) is a major public health problem and the most common form of chronic liver disease, affecting 25% of the global population. Although NAFLD is closely linked with obesity, insulin resistance, and type 2 diabetes mellitus, knowledge on its pathogenesis remains incomplete. Emerging data have underscored the importance of Rho-kinase (Rho-associated coiled-coil-containing kinase [ROCK]) action in the maintenance of normal hepatic lipid homeostasis. In particular, pharmacological blockade of ROCK in hepatocytes or hepatic stellate cells prevents the progression of liver diseases such as NAFLD and fibrosis. Moreover, mice lacking hepatic ROCK1 are protected against obesity-induced fatty liver diseases by suppressing hepatic de novo lipogenesis. Here we review the roles of ROCK as an indispensable regulator of obesity-induced fatty liver disease and highlight the key cellular pathway governing hepatic lipid accumulation, with focus on de novo lipogenesis and its impact on therapeutic potential. Consequently, a comprehensive understanding of the metabolic milieu linking to liver dysfunction triggered by ROCK activation may help identify new targets for treating fatty liver diseases such as NAFLD.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent20
dc.format.extent495182
dc.identifier.doi10.4093/DMJ.2021.0197
dc.identifier.issn2233-6079
dc.identifier.otherPURE: 34467067
dc.identifier.otherPURE UUID: 0c324675-ec34-4ab1-97e7-a6b0699a1664
dc.identifier.otherScopus: 85117199115
dc.identifier.urihttp://hdl.handle.net/10362/127068
dc.identifier.urlhttps://www.scopus.com/pages/publications/85117199115
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAMP-activated protein kinase
dc.subjectDiet
dc.subjectHigh-fat
dc.subjectLipogenesis
dc.subjectNonalcoholic fatty liver disease
dc.subjectRho-kinase
dc.subjectEndocrinology, Diabetes and Metabolism
dc.subjectSDG 3 - Good Health and Well-being
dc.titleRho-kinase as a therapeutic target for nonalcoholic fatty liver diseasesen
dc.typereview
degois.publication.firstPage655
degois.publication.issue5
degois.publication.lastPage674
degois.publication.titleDiabetes and Metabolism Journal
degois.publication.volume45
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
dmj_2021_0197.pdf
Tamanho:
483.58 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS: CEDOC - Artigos em revista internacional com arbitragem científica